Search Result

Isoforms Recommended:	CB1

Results for "

CB1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Akt (1) AMPK (1) Androgen Receptor (1) Apoptosis (1) Arrestin (1) Autophagy (9) Bacterial (4) Biochemical Assay Reagents (2) Cannabinoid Receptor (117) Cytochrome P450 (1) Endogenous Metabolite (18) FAAH (5) Fatty Acid Synthase (FASN) (1) GlyT (1) GPR55 (4) Isotope-Labeled Compounds (3) mAChR (1) MAGL (1) NF-κB (1) NO Synthase (2) Parasite (1) PDHK (1) PPAR (1) TRP Channel (12)
By Research Areas:	Cancer (15) Cardiovascular Disease (2) Endocrinology (1) Infection (7) Inflammation/Immunology (18) Metabolic Disease (31) Neurological Disease (71)

134

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

CB1 antagonist 4	Cannabinoid Receptor	Metabolic Disease
CB1 antagonist 4 (compound 8) is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist. CB1 antagonist 4 shows limited penetrance to the brain in order to minimize or prevent CNS adverse reactions, and preserves potential antiobesity effects. CB1 antagonist 4 reduces propensity for psychiatric side effects ^[1] .

CB1 agonist 1	Cannabinoid Receptor	Neurological Disease
CB1 agonist 1 (compound 22) is an agonist of *CB1. CB1* agonist 1 shows affinity to CB1 receptor with an pIC₅₀ value of 5.7. CB1 agonist 1 can be used for the research of brain disorders ^[1].

MRL-650 CB1 inverse agonist 1	Cannabinoid Receptor	Metabolic Disease
MRL-650 (CB1 inverse agonist 1) is a highly potent, orally active, and specific inverse agonist of CB1 receptor with IC₅₀s of 7.5 nM and 4100 nM for *CB1* and CB2 receptors, respectively. Anorexigenic effects ^[1].

CB1 inverse agonist 2	Cannabinoid Receptor	Neurological Disease
CB1 inverse agonist 2 is an orally active inverse agonist of Cannabinoid Receptor CB1. CB1 inverse agonist 2 effectively inhibits CP55940-induced hypothermia and anorexia in mice model ^[1].

CB1 antagonist 1	Cannabinoid Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
CB1 antagonist 1 is an antagonist of CB1 receptor, used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.

CB1 antagonist 2 AM4113	Cannabinoid Receptor	Neurological Disease
CB1 antagonist 2 is caimabinoid 1 (CB1) antagonist extracted from patent WO2016184310A1, compound 3, inhibits CB1 in vivo with an IC₅₀ of 25.5 nM ^[1].

CB1/2 agonist 3	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a *CB1/CB2* (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with K_i values of 5.9 nM and 3.5 nM, respectively ^[1].

CB1/2 agonist 4	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 4 is a full *CB1* agonist and CB2 partial agonist with EC₅₀ values of 15.09 nM and 1.16 nM, respectively. CB1/2 agonist 4 also has hCB1 and hCB2 receptor affinities with K_i values of 1.1 nM and 4.2 nM, respectively. CB1/2 agonist 4 has a significant antinociceptive activity, and also can activate cannabinoid and *TRPV1* receptor with values of IC₅₀ and EC₅₀ is 0.8 μM and 0.12 μM, respectively ^[1].

CB1-IN-2	Cannabinoid Receptor	Metabolic Disease
CB1-IN-2 (Compound 4g) is a selective *CB₁* inhibitor with an IC₅₀ of 0.644 μM. CB1-IN-2 can penetrates BBB and might cause CNS side effect similar with Rimonabant ^[1].

CB1/2 agonist 1	Cannabinoid Receptor	Inflammation/Immunology
CB1/2 agonist 1 is a potent and cross the blood-brain barrier *CB1/2* agonist with EC₅₀s of 56.15, 11.63 nM for CB1R and CB2R, respectively. CB1/2 agonist 1 reduces glutamate release and LPS-induced activation of microglial cells. CB1/2 agonist 1 shows anti-inflammatory and antinociceptive effects. CB1/2 agonist 1 has the potential for the research of multiple sclerosis ^[1].

CB1/2 agonist 2	Cannabinoid Receptor	Inflammation/Immunology
CB1/2 agonist 2 (compound 23) is a potent non-selective cannabinoid ligand, with K_i values of 3.5 and 1.2 nM, respectively. CB1/2 agonist 2 can behave as a full *CB1* agonist and CB2 competitive inverse agonist. CB1/2 agonist 2 shows antinociceptive activity ^[1].

CB1-IN-1 BPRCB1184	Cannabinoid Receptor	Neurological Disease
CB1-IN-1 (BPRCB1184) is a peripherally restricted CB1R antagonist, with Ki of 0.3 nM and 21 nM for CB1R (EC50 = 3 nM) and CB2R, respectively.

CB1R/AMPK modulator 1	AMPK Cannabinoid Receptor	Metabolic Disease
CB1R/AMPK modulator 1 (Compound 38-S) is an orally active *CB1R/AMPK* modulator, with an K_i of 0.81 nM and an IC₅₀ of 3.9 nM for CB1R. CB1R/AMPK modulator 1 activates AMPK. CB1R/AMPK modulator 1 reduces food intake and body weight, and improves glucose tolerance and insulin sensitivity ^[1].

CB1R Allosteric modulator 1	Cannabinoid Receptor	Others
CB1R Allosteric modulator 1 (compound 11) is a potent *CB1R* allosteric modulator. CB1R Allosteric modulator 1 shows negatively affects the functional activity of orthosteric ligands (NAM) at CB1Rs ^[1].

CB1R Allosteric modulator 2	Cannabinoid Receptor	Others
CB1R Allosteric modulator 2 (compound 18) is a potent *CB1R* allosteric modulator. CB1R Allosteric modulator 2 shows negatively affects the functional activity of orthosteric ligands (NAM) at CB1Rs ^[1].

CB1R antagonist 1	Cannabinoid Receptor	Metabolic Disease
CB1R Allosteric modulator 5, a selective **cannabinoid-1 receptor (CB1R) inverse agonist with an IC₅₀ value of 4.2 μM and EC₅₀** value of ＞10 μM. CB1R Allosteric modulator 5 can be used for the research of metabolic and obesity ^[1].

CB1R Allosteric modulator 3	Cannabinoid Receptor Arrestin	Neurological Disease
CB1R Allosteric modulator 3 is a CB1R positive allosteric modulator. CB1R Allosteric modulator 3 has potent inhibition of cAMP and β-Arrestin with EC₅₀ values of 0.018 μM and 1.241 μM, respectively ^[1].

CB1R Allosteric modulator 4	Cannabinoid Receptor	Others
CB1R Allosteric modulator 4 is a positive allosteric modulator of cannabinoid type-1 (CB1R) with good biological activity. CB1R Allosteric modulator 4 inhibits cAMP production and shows robust activity in β-arrestin-2 recruitment ^[1].

NESS 0327	Cannabinoid Receptor	Neurological Disease
NESS 0327 is a cannabinoid antagonist with high selectivity for the cannabinoid CB1 receptor. NESS 0327 is more than 60,000-fold selective for the CB1 receptor ^[1].

Ibipinabant SLV319; BMS-646256	Cannabinoid Receptor	Metabolic Disease
Ibipinabant (SLV319) is a potent, selective and orally active antagonist of *cannabinoid CB1* receptor, with a K_i** of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (K_i=7943 nM). Ibipinabant can be used for the research of obesity and diabetic ^[1] .

CBR Agonist-2	Cannabinoid Receptor	Neurological Disease
CBR Agonist-2 is a *CB1* agonist (CB1R; CB1 ligand) with an EC₅₀ and a K_i of 960 nM and 970 nM, respectively. CBR Agonist-2 is a promising tool for investigating the involvement of hCB1R in disorders associated with the endocannabinoid system ^[1].

AM8936	Cannabinoid Receptor	Neurological Disease Metabolic Disease
AM8936 acts as a balanced and potent cannabinoid receptor type-1 (CB1) agonist in functional assays (EC₅₀s of 8.6 and 1.4 nM for rCB1 and hCB1, respectively). AM8936 exhibits high affinity for rat CB1 (rCB1) with K_i of 0.55 nM. AM8936 is a potent and efficacious CB1 agonist in vivo. AM8936 can be used for the research of CNS and metabolic disorders, pain, glaucoma, etc ^[1].

CB65	Cannabinoid Receptor	Inflammation/Immunology
CB65 is a potent and high affinity CB2 selective agonist with a K_i value of 3.3 nM. CB65 exhibits a K_i of >1000 nM for CB1 receptor ^[1].

PSB-SB1202	Cannabinoid Receptor	Neurological Disease
PSB-SB1202 (Compound 21a) is a phenyl coumarin compound. PSB-SB1202 is a *CB1/CB2* agonist with EC₅₀ values of 56 and 14 nM, and K_i values of 32 and 49 nM, respectively ^[1].

AM281	Cannabinoid Receptor	Neurological Disease
AM281 is a selective CB1 receptor antagonist with an IC₅₀ of 9.91 nM. AM281 inhibits CB2 receptor with an IC₅₀ of 13000 nM ^[1].

AZD1940	Cannabinoid Receptor	Neurological Disease
AZD1940 is an orally active, high affinity *cannabinoid CB1/CB2 receptor* agonist with pK_i values of 7.93 and 9.06 for human CB1R and CB2R, respectively. AZD1940 shows a robust analgesia action ^[1] .

TM38837	Cannabinoid Receptor	Metabolic Disease
CB1 antagonist 4 is a inverse agonist of cannabinoid receptor 1 (CB1) with an IC₅₀ of 0.4 nM. CB1 antagonist 4 can reduce body weight, improve plasma inflammatory markers and glucose homeostasis ^[1].

Org 27569	Cannabinoid Receptor	Neurological Disease
Org 27569 is a potent CB1 receptor allosteric modulator, which increases agonist binding, yet blocks agonist-induced CB1 signaling.

S-Methoprene (+)-Methoprene; (7S)-Methoprene
S-Methoprene is an insect juvenile hormone analog and effective insecticide that blocks the transition from pupa to adult. S-Methoprene is also a CB(1) receptor ligand and inhibits the binding of the CB1 receptor antagonist [ ³H]CP-55940 to the CB1 receptor (IC₅₀: 19.31 μM) ^[1] .

URB447	Cannabinoid Receptor	Metabolic Disease
URB447 is a peripherally restricted *CB₁* cannabinoid antagonist (IC₅₀: 313 nM and 41 nM for rat CB1 and human CB2 receptor respectively ). URB447 lowers food intake and body-weight gain in mice without entering the brain or antagonizing central CB₁-dependent responses. URB447 can be used for research of obesity ^[1].

LY320135	Cannabinoid Receptor 5-HT Receptor mAChR	Neurological Disease
LY320135 is a potent and selective antagonist of *CB1* receptor, with a K_i of 141 nM. LY320135 also binds to 5-HT₂ and muscarinic receptors with K_is of 6.4 μM and 2.1 μM, respectively. LY320135 exhibits neuroprotective effect ^[1] .

O-2050	Cannabinoid Receptor	Neurological Disease
O-2050 is a high affinity *cannabinoid CB₁* receptor antagonist with a K_i** of 2.5 nM. O-2050 inhibits cannabinoid CB₂ receptor (K_i=0.2 nM). O-2050 can cause locomotor stimulation in mice ^[1].

Bay 59-3074	Cannabinoid Receptor	Cancer
Bay 59-3074 is a selective cannabinoid CB₁/CB₂ receptor partial agonist with K_i values of 48.3 and 45.5 nM at human *CB₁* and CB₂ receptors, respectively. Bay 59-3074 has analgesic properties ^[1].

2-Linoleoyl glycerol 2-Monolinolein; 2-Monolinoleoylglycerol	Cannabinoid Receptor	Neurological Disease
2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid *CB1* receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) ^[1] .

BAY 38-7271	Cannabinoid Receptor	Neurological Disease
BAY 38-7271 is selective and highly potent and cannabinoid CB₁/CB₂ receptor agonist, with K_is of 1.85 nM and 5.96 nM for recombinant human CB₁ receptor and CB₂ receptor, respectively. BAY 38-7271 has strong neuroprotective properties ^[1].

2-Palmitoylglycerol 2-Palm-Gl	Cannabinoid Receptor	Neurological Disease
2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 ^[1].

IDFP iso-Prdodecylfluorophosphonate	Cannabinoid Receptor	Neurological Disease
IDFP (iso-Prdodecylfluorophosphonate) is a chemical affinity probe for the cannabinoid *CB1* receptor ^[1].

GAT228	Cannabinoid Receptor	Inflammation/Immunology
GAT228, the enantiomer of GAT211, is an allosteric cannabinoid receptor 1 (CB1) ligand ^[1].

(±)-Ibipinabant (±)-SLV319; (±)-BMS-646256	Cannabinoid Receptor	Metabolic Disease
(±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC₅₀ of 22 nM.

MJ15	Cannabinoid Receptor	Metabolic Disease
MJ15 is a potent and selective CB1 receptor antagonist with a K_i of 27.2 pM and an IC₅₀ of 118.9 pM for rat CB1 receptors. MJ15 exhibits potency in obesity and hyperlipidemia models. MJ15 inhibits food intake and increases in body weight in diet-induced obese rats and mice ^[1].

A-836339	Cannabinoid Receptor	Neurological Disease
A-836339 is a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptors.

Virodhamine hydrochloride	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine (hydrochloride) is a cannabinoid *CB1* receptor partial agonist and cannabinoid CB2 receptor full agonist ^[1].

OLHHA	Cannabinoid Receptor PPAR	Metabolic Disease
OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC₅₀ value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD) ^[1] .

ANEB-001	Cannabinoid Receptor	Neurological Disease
ANEB-001 is an orally active *CB1* inhibitor, can be used to research acute cannabinoid intoxication ^[1].

Monlunabant (S)-MRI-1891	Cannabinoid Receptor	Neurological Disease
Monlunabant ((S)-MRI-1891) is a solid dispersions compound, as well as a cannabinoid CB1 receptor inhibitor ^[1].

(R)-Monlunabant (R)-MRI-1891	Cannabinoid Receptor	Metabolic Disease
(R)-Monlunabant ((R)-MRI-1891) is a CB1 receptor mediators for research of obesity and metabolic disease ^[1]

Cat. No.	Product Name	Type

HY-110004

ACEA Arachidonyl-2-chloroethylamide	Biochemical Assay Reagents
ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory ^[1].

HY-W127407

Glycerophospho-N-arachidonoyl ethanolamine

Biochemical Assay Reagents

Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.

Cat. No.	Product Name	Target	Research Area

HY-P1397A

RVD-Hpα TFA	Cannabinoid Receptor
RVD-Hpα TFA is the N-terminally extended form of human hemopressin that acts as a selective CB1 receptor agonist. RVD-Hpα TFA increases intracellular Ca ²⁺ levels in cells expressing CB1 receptors in vitro. RVD-Hpα TFA also high affinity CB2 positive allosteric modulator (K_i=50 nM).

HY-P1091

Hemopressin (human, mouse)	Cannabinoid Receptor	Neurological Disease
Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of *CB1* cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models ^[1] .

HY-P1397

RVD-Hpα	Cannabinoid Receptor	Neurological Disease
RVD-Hpα, an α-hemoglobin-derived peptide containing three additional amino acids, is a CB1 cannabinoid receptor agonist. RVD-Hpα is a positive allosteric modulator of cannabinoid receptor 2 ^[1] .

HY-P1090

Hemopressin(rat)	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of *CB1* cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models ^[1] .

HY-P1091A

Hemopressin(human, mouse) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin TFA is orally active, selective and inverse agonist of *CB1* cannabinoid receptors. Hemopressin TFA exerts antinociceptive action in inflammatory pain models ^[1] .

HY-P1090A

Hemopressin(rat) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of *CB1* cannabinoid receptors. Hemopressin(rat) TFA exerts antinociceptive action in inflammatory pain models ^[1] .

Species:	Human (1) Rat (1)
Tag:	His (2)
Source:	HEK293 (1) E. coli Cell-free (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P700408

	CNR1 Protein-VLP, Human (HEK293, His) cannabinoid receptor 1 (brain); CNR; cannabinoid receptor 1; CANN6; CB R; CB1; CB1A; CB1K5; central cannabinoid receptor; CB-R; CB1R	Human	HEK293
	CNR1 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays.

HY-P702254

	CNR1 Protein, Rat (Cell-Free, His) Cannabinoid receptor 1; Brain-type cannabinoid receptor; CB-R; CB1	Rat	E. coli Cell-free
	The CNR1 protein is a G-protein-coupled receptor for cannabinoids, including cannabinoids and endocannabinoids such as 2-AG, which mediates diverse effects on food intake, memory, and pain. It regulates mitochondrial respiration and inhibits leptin-induced ROS formation. CNR1 Protein, Rat (Cell-Free, His) is the recombinant rat-derived CNR1 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of CNR1 Protein, Rat (Cell-Free, His) is 473 a.a., with molecular weight of 58.9 kDa.

Cat. No.	Product Name	Chemical Structure

HY-B0151S2

Pregnenolone-d4-1

Pregnenolone-d₄-1 is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication[1][2]. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-B0151S1

Pregnenolone-13C2,d2

Pregnenolone- ¹³C₂,d₂ is the deuterium and ¹³C labeled Pregnenolone (HY-B0151). Pregnenolone is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[1][2][3][4].

HY-B0151S

Pregnenolone-d4

Pregnenolone-d₄ is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication[1][2]. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-110189S1

Pregnenolone monosulfate-d4 sodium

Pregnenolone monosulfate-d₄ (sodium) is the deuterium labeled Pregnenolone monosulfate. Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium can protect the brain from cannabis intoxication[1][2]. Pregnenolone monosulfate sodium is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-14136S

Rimonabant-d10
Rimonabant-d₁₀ is deuterium labeled Rimonabant. Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-110189S

Pregnenolone monosulfate sodium-13C2,d2

Pregnenolone monosulfate (sodium)- ¹³C₂,d₂ is the ¹³C- and deuterium labeled Pregnenolone monosulfate sodium. Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium salt acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium salt can protect the brain from cannabis intoxication[1][2]. Pregnenolone monosulfate sodium salt is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-14137S

Rimonabant-d10 hydrochloride
Rimonabant-d₁₀ (hydrochloride) is the deuterium labeled Rimonabant hydrochloride. Rimonabant hydrochloride (SR 141716A hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an Ki of 1.8 nM. Rimonabant hHydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3)[1][2].

Cat. No.	Product Name	Application	Reactivity

HY-P82605

Phospho-Cannabinoid Receptor I (Ser316) Antibody (YA2350)

CNR1; CNR; Cannabinoid receptor 1; CB-R; CB1; CANN6
WB Human
HY-P81627

CB1 Antibody (YA1372)

CNR1; CNR; Cannabinoid receptor 1; CB-R; CB1; CANN6
FC, ELISA Human

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

CB1

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products